N
|
ew research finds that estrogen
improves insulin sensitivity and details the mechanism behind this effect. The
findings have a "profound impact on our understanding of obesity and
diabetes, as well as potential dietary interventions," say the researchers.
The female sex hormone may have
significant metabolic benefits.
About 84 million people in the United States are living with
prediabetes, a condition in which blood sugar levels are very high but not high
enough to warrant a diagnosis of type 2 diabetes.
Usually,
prediabetes occurs in people with insulin resistance —
a condition in which the cells in some vital organs do not respond well
to insulin and therefore do not absorb enough
glucose from the blood.
But
what if there was a hormone that could lower insulin resistance and the
production of glucose?
Researchers
believe that estrogen has the
potential to do so, and consequently, to reduce the prevalence of type 2
diabetes.
Currently, over 100 million people in the U.S. are living with diabetes or
prediabetes, and estimates show that over 30 million adults have type 2
diabetes.
Shaodong
Guo, Ph.D., an associate professor in the Department of Nutrition and Food
Science at Texas A&M University in College Station, led the new research.
The study appears in Diabetes, the journal of the American Diabetes Association.
Why study the metabolic effect of estrogen?
Guo
explains the motivation for the study, saying that previous observational
research has uncovered a link between a lower incidence of type 2 diabetes and
premenopausal women.
Furthermore,
clinical and animal studies found a strong link between estrogen deficiency and
metabolic disorders.
"Premenopausal
women exhibit enhanced insulin sensitivity and reduced incidence of type 2
diabetes, compared with age-equivalent men," Guo says. "But this
advantage disappears after menopause with
disrupted glucose homeostasis, in part owing to a reduction in circulating
estrogen."
However,
researchers have not yet been able to elucidate the mechanisms responsible for
these connections.
Also,
blindly using estrogen as a potential treatment for type 2 diabetes and other
prediabetes metabolic dysfunctions could have serious side effects. For
example, stroke, breast cancer, blood
clots, and heart attack are some
of the health risks associated with estrogen therapy.
"This
is why it is so important to understand the tissue-specific action of estrogen
and its molecular mechanism in metabolic regulation," Guo explains.
"Once that mechanism is understood, it will aid in the development of
targeted estrogen mimics that can provide the therapeutic benefits without unwanted
side effects."
Foxo1 mediates estrogen's metabolic effects
In
the new study, the researchers "wanted to understand the mechanism by
which estrogen regulates gluconeogenesis by means of interaction with hepatic
Foxo1," the lead investigator continues, referring to a gene also called
forkhead box O1.
Gluconeogenesis
describes the synthesis process through which glucose is generated.
The
Foxo1 gene encodes a transcription factor, or a type of protein that helps activate
or deactivate other genes.
Foxo1
"is the main target of insulin signaling and regulates metabolic
homeostasis in response to oxidative stress," the U.S. National
Library of Medicine report.
As
Guo explains, "Foxo1 has an important role in the regulation of glucose
production through insulin signaling. It is an important component of
insulin-signaling cascades regulating cellular growth, differentiation, and
metabolism."
To
investigate the gene's role and how it interacts with estrogen, the researchers
studied male mice, female mice whose ovaries had been removed, and both male
and female mice whose Foxo1 genes had been knocked out in the liver.
The
researchers used a subcutaneous implant that released estrogen in the mice.
This implant "improved insulin sensitivity and suppressed
gluconeogenesis" in the male mice as well as in the ovariectomized female
mice.
However, the implant did not affect the rodents
whose liver-specific Foxo1 genes had been knocked out. "This suggests
Foxo1 is required for estrogen to be effective in suppressing
gluconeogenesis," Guo explains.
The
researcher reports, "We further demonstrated that estrogen suppresses
hepatic glucose production through activation of estrogen receptor signaling,
which can be independent of insulin receptor substrates Irs1 and Irs2."
"This
reveals an important mechanism for estrogen in the regulation of glucose
homeostasis," Guo says. The beneficial effects of estrogen on glucose
homeostasis may be controlled by gluconeogenesis — which is, in turn, mediated
by liver-specific Foxo1 — not by promoting the uptake of glucose in the
muscles.
Therapeutic and dietary implications
Guo
explains the therapeutic implications of the findings. "The identification
of tissue-specific actions of estrogen and direct targets of estrogen receptors
will facilitate the development of novel selective ligands that prevent type 2
diabetes, cardiovascular disease, and obesity without promoting abnormal
sex characteristics or breast cancer."
Finally,
the researcher also comments on the dietary implications of the study. Certain
foods, such as soybeans, tofu, and miso soup contain phytoestrogens,
which may have the same beneficial effects on metabolic health.
The
study "provides a fundamental understanding that dietary intervention can
play a crucial role in controlling obesity, diabetes, and associated chronic
diseases," says Guo.
"[W]e investigated the role of
estrogen in control of glucose homeostasis, which has profound impact on our
understanding of obesity and diabetes as well as potential dietary
interventions."
No comments:
Post a Comment